The Global Prenatal And Newborn Genetic Testing Market was valued at USD 8.1 billion in 2024 and is estimated to grow at a CAGR of 12.8% to reach USD 9.1 billion by 2034.
The increasing prevalence of genetic conditions such as Down syndrome, cystic fibrosis, and spinal muscular atrophy is driving demand for early detection through prenatal and newborn genetic testing. Expectant parents are increasingly seeking reassurance and early intervention options.
Major players in the prenatal and newborn genetic testing market are Genes2me, Trivitron Healthcare, Retrogen, Aetna, Fulgent Genetics, Eurofins, Illumina, CENTOGENE, Genelab (Clevergene), Thermo Fisher Scientific, Myriad Genetics, Natera, Revvity, LaCAR, BGI Group, BillionToOne, LabCorp, Agilent, and Yourgene Health.
To strengthen their position in the prenatal and newborn genetic testing market, companies are pursuing a mix of innovation-driven and expansion-focused strategies. Many are investing in R&D to develop high-throughput platforms and broaden their test portfolios to cover rare genetic conditions and inherited disorders. Strategic collaborations with hospitals, academic institutions, and technology partners are enabling faster market penetration and access to diverse patient populations.
This product will be delivered within 2-4 business days.
The increasing prevalence of genetic conditions such as Down syndrome, cystic fibrosis, and spinal muscular atrophy is driving demand for early detection through prenatal and newborn genetic testing. Expectant parents are increasingly seeking reassurance and early intervention options.
Rising Adoption of Kits and Reagents Segment
The kits and reagents segment held a significant share in 2024, as these consumables are essential for both clinical diagnostics and research workflows. Laboratories and diagnostic centers depend on high-quality, reliable reagents to ensure accurate and reproducible results. As testing volumes grow, driven by increasing demand for early genetic screening, the recurring nature of consumable use continues to boost segment performance.Increasing Demand for the Prenatal Tests Segment
The prenatal tests segment held a sizeable share in 2024, owing to rising maternal age, increased risk awareness, and strong clinical adoption of non-invasive and invasive testing options. These tests help detect chromosomal abnormalities, genetic mutations, and fetal anomalies early in pregnancy, enabling more informed clinical decision-making. The shift toward first-trimester screening and the inclusion of expanded genetic panels have fueled sustained growth in this segment.cfDNA to Gain Traction
The cell-free DNA (cfDNA) testing segment held a sustainable share in 2024, driven by a non-invasive, highly accurate method to screen for common chromosomal conditions like trisomy 21, 18, and 13. This method analyzes fetal DNA fragments circulating in maternal blood, reducing the need for invasive procedures like amniocentesis.North America to Emerge as a Propelling Region
North America prenatal and newborn genetic testing market is poised to grow at a sizeable share in 2024, driven by strong healthcare infrastructure, advanced lab capabilities, and widespread access to genetic services. In the U.S. and Canada, early screening is widely adopted, supported by favorable insurance coverage, regulatory backing, and increasing public awareness. Continued investment in genomic medicine, expansion of NIPT guidelines, and integration of AI-based diagnostic tools are further fueling market growth across this region.Major players in the prenatal and newborn genetic testing market are Genes2me, Trivitron Healthcare, Retrogen, Aetna, Fulgent Genetics, Eurofins, Illumina, CENTOGENE, Genelab (Clevergene), Thermo Fisher Scientific, Myriad Genetics, Natera, Revvity, LaCAR, BGI Group, BillionToOne, LabCorp, Agilent, and Yourgene Health.
To strengthen their position in the prenatal and newborn genetic testing market, companies are pursuing a mix of innovation-driven and expansion-focused strategies. Many are investing in R&D to develop high-throughput platforms and broaden their test portfolios to cover rare genetic conditions and inherited disorders. Strategic collaborations with hospitals, academic institutions, and technology partners are enabling faster market penetration and access to diverse patient populations.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product and Services, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Test Type, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 10 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 11 Company Profiles
Companies Mentioned
The key companies profiled in this Prenatal and Newborn Genetic Testing market report include:- Aetna
- Agilent
- BGI Group
- BilliontoOne
- CENTOGENE
- Eurofins
- Fulgent Genetics
- Genelab (Clevergene)
- Genes2me
- Illumina
- Labcorp
- LaCAR
- Myriad Genetics
- Natera
- Retrogen
- Revvity
- Thermo Fisher Scientific
- Trivitron Healthcare
- Yourgene Health
